Navigation Links
CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008

Company Announces 15% Quarterly Revenue Increase Over Prior Year and Sixth

Consecutive Quarter of Year Over Year Revenue Growth

SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for fiscal second quarter 2008. Highlights include 18% revenue increase for first half fiscal 2008, 15% quarterly revenue increase over prior year and sixth consecutive quarter of year over year revenue growth.

Sales Highlights of Second Quarter 2008 Compared with Second Quarter 2007

-- Net sales increased 15% to $6.2 million, up from $5.4 million

-- Over 8,200 ICG monitors and modules sold to date, up 12% from 7,300 one year ago

-- ICG device sales totaled 217 units, including 137 ICG monitors, 108 of which were BioZ Dx systems, 14 BioZ monitors, and 15 Medis ICG monitors

-- ICG sensor revenue increased 1% to $1.7 million, comprising 28% of total sales, and increased 14% sequentially over first quarter 2008

-- International and new market revenue grew 11% to $782,000

Key Financial Results of Second Quarter 2008 Compared with Second Quarter 2007

-- Gross profit margin was 71%, up from 63%

-- Operating loss was $476,000, an improvement of $1.0 million, or 68%, from $1.5 million

-- Net loss was reduced 62% to $732,000, or ($0.10) per diluted share, from a net loss from continuing operations of $1.9 million, or ($0.28) per diluted share

-- Operating cash use was $490,000, down 43%, from an operating cash use from continuing operations of $860,000

-- Cash, cash equivalents and short-term investments at May 31, 2008, of $6.9 million, up 47% from $4.7 million at May 31, 2007

Additional Key Operating Milestones for the Second Quarter 2008

-- Released significant ICG study demonstrating nearly three times the national average blood pressure control rates at the American Society for Hypertension Annual Scientific meeting
-- Completed one-for-seven reverse split of company's common stock

-- Regained compliance with Nasdaq listing requirements

Second Quarter 2008 Operating Results Discussion

The Company reported a net sales increase of 15% to $6.2 million. ICG sales growth was due to a combination of 8% higher average domestic ICG monitor sales prices, a 20% increase in domestic ICG System sales and an 11% improvement in international and new market revenue (primarily due to increased revenue from pharmaceutical companies). The higher average domestic sales price indicates continued physician acceptance and a solid value proposition for ICG technology. The improvement in international and new market revenue is a result of the Company's increased focus on non-Medicare reimbursement dependant markets. Recurring sensor revenue grew 14% sequentially from first quarter 2008 to $1.7 million, and was up 1% compared to the same period in 2007.

Gross margin as a percentage of sales increased from 63% to 71% in the second quarter of 2008, largely due to a higher net average sales price per unit, lower manufacturing expenses and reduced inventory charges related to potential excess, slow-moving or obsolete inventory. Operating expenses were held flat at $4.9 million and increased revenue, along with improved gross margins, drove a 68% improvement in the operating loss. The reduced operating loss, coupled with sound working capital management, resulted in a 43% reduction in operating cash usage to $490,000 in the quarter, down from an $860,000 operating cash use from continuing operations in the same quarter of 2007.

CEO Comments and Outlook

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We are very pleased with the 18% revenue growth achieved in the first half of 2008 and 15% during the second quarter. Sales momentum continues strong and with steady improvement throughout the business, we completed our sixth consecutive quarter of year over year revenue growth. We are making very good progress in expanding gross margins and reducing the operating loss, down 68% to $476,000, which includes $247,000 of non-cash charges for depreciation, amortization and equity compensation. We see sizable opportunity to continue to grow the business and recently hired 12 new sales and clinical personnel to replace open positions and further expand our field sales force. Our operating plan remains to achieve at least 15% revenue growth for 2008 and deliver positive operating cash flow in the fourth quarter."

The Company also announced the retirement of Russ Bergen as its Vice President of Operations. Perry stated, "We are grateful for the fine contribution that Russ has made to CardioDynamics as our Vice President of Operations for the past ten years. He was responsible for establishing and growing our excellent operations team that consistently delivered high quality products and services, and also oversaw the manufacturing and launch of three generations of proprietary, impedance cardiography systems. We wish him the very best in this new stage of life."

Conference Call Information

Michael K. Perry, Chief Executive Officer, and Steve P. Loomis, Chief Financial Officer, will host a summary of CardioDynamics' second quarter 2008 results in a conference call today, Tuesday, July 1, 2008, at 4:30 p.m. (EDT). To access the conference call, dial 800-346-7359 (Code 7784). International participants can call 973-528-0008 (Code 7784). A replay of the call will be available for 30 days following the call at 800-332-6854 (Code 7784). The international replay number is 973-528-0005 (Code 7784). The Internet webcast can be accessed through the Investor Relations section of the Company's website at or at

About CardioDynamics

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of an important medical technology called impedance cardiography (ICG). The Company develops, manufactures and markets noninvasive ICG products and medical device electrodes. The Company's ICG Systems are being used by physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Healthcare, Philips Medical Systems and Mindray. For additional information, please refer to the company's Web site at

Forward-Looking (Safe Harbor) Statement

Except for historical and factual information contained herein, this press release contains forward-looking statements, such as revenue growth rates and cash flow projections, increasing physician acceptance of ICG technology, diversification and new market development, success of clinical trials or investments in core technology, the accuracy of which is necessarily subject to uncertainties and risks including the Company's primary dependence on the BioZ product line, and various uncertainties characteristic of early stage companies, as well as other risks detailed in the Company's filings with the SEC, including its 2007 Form 10-K. The Company does not undertake to update the disclosures contained in this press release.

CardioDynamics International Corporation

In thousands, except per share data (unaudited)

Selected Consolidated Three Months Ended Six Months Ended

Operational Results May 31, May 31,

2008 2007 2008 2007

Net sales $6,180 $5,380 $11,942 $10,107

Cost of sales 1,772 1,966 3,547 3,186

Gross margin 4,408 3,414 8,395 6,921

Research and development 370 454 684 897

Selling and marketing 3,721 3,680 7,443 7,124

General and administrative 761 720 1,532 1,665

Amortization of intangible assets 32 30 64 85

Loss from operations (476) (1,470) (1,328) (2,850)

Other expense, net (192) (241) (358) (448)

Loss before income taxes and

minority interest (668) (1,711) (1,686) (3,298)

Minority interest in income of

subsidiary (11) (21) (145) (35)

Income tax provision (53) (196) (516) (250)

Income (loss) from discontinued

operations - (11,102) 127 (11,109)

Net loss $(732) $(13,030) $(2,220) $(14,692)

Net loss per common share:

Basic and diluted $(0.10) $(1.86) $(0.31) $(2.10)

Weighted-average shares used in per

share calculation:

Basic and diluted 7,193 7,005 7,150 6,990

Selected Consolidated May 31, November 30,

Balance Sheet Data 2008 2007

Cash and cash equivalents $6,936 $8,362

Accounts receivable, net 3,797 4,475

Inventory, net 1,196 1,670

Total current assets 12,472 15,164

Long-term assets 4,778 4,703

Total assets 17,250 19,867

Total current liabilities 8,151 5,620

Long-term liabilities 910 4,318

Total liabilities 9,061 9,938

Minority interest 495 407

Shareholders' equity 7,694 9,522

SOURCE CardioDynamics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CardioDynamics Announces Third Quarter 2007 Conference Call and Webcast
2. CardioDynamics Announces Strategic Alliance With Leading Medical Equipment Manufacturer in India
3. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
4. CardioDynamics Board of Directors Proposes Reverse Split 1:7 of Companys Shares
5. CardioDynamics Reports 22% Revenue Growth in First Quarter 2008
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. CardioDynamics Announces Second Quarter 2008 Conference Call and Webcast
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., ... Provider (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the ... Center solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Trevor and Taylor Crabb have unveiled an exciting ... chance to represent the United States. This hybrid crowdfunding campaign is designed ... their journey in addition to offering corporate sponsors with some great marketing deliverables with ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of Professional ... VIP Woman of the Year Circle. She is recognized with this prestigious distinction for ... for professional women, boasting more than 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... December 1, 2015 Biovicas ... Study Group (IBCSG, Bern ) ... i en klinisk studie av palbociclib, ett nytt ... --> Studien, med namn PYTHIA, kommer följa ... läkemedel i kombination med palbociclib, som tillhör klassen ...
(Date:11/30/2015)... Dec. 1, 2015 Researchers have developed software ... part thickness and checks for motion, positioning and beam ... study presented today at the annual meeting of the ... (RSNA). Steven Don , M.D., associate professor ... School of Medicine in St. Louis, Mo. ...
(Date:11/30/2015)... TOKYO , 1. Dezember 2015 /PRNewswire/ ... größte Messe und Konferenz für Entwicklung ... 20. bis 22. April 2016 in ... Foto:- ... Logo: Logo: ...
Breaking Medicine Technology: